Biomimetic Therapeutics Inc trades in the stock market as ticker BMTI. Business Summary & Profile For Biomimetic Therapeutics Inc.

Biomimetic Therapeutics Inc

BioMimetic Therapeutics, Inc., a biotechnology company, engages in the development and commercialization of regenerative protein therapeutic products primarily used for bone and tissue regeneration, repair and healing of musculoskeletal injuries, and conditions affecting bones, tendons, ligaments, and cartilage. The company’s orthopedic products include Augment Bone Graft for open fracture and fusion treatment; and Augment Injectable Bone Graft for open or closed fracture treatment and minimally invasive fracture/fusion treatment. Its products also comprise Augment Rotator Cuff Graft for rotator cuff tendon to bone repair; Augment OCD for cartilage and bone repair; TBD for the treatment of injuries due to tendon overuse; and Augment Bone Graft for spine fusion. The company was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in July 2005. BioMimetic Therapeutics, Inc. was founded in 1999 and is headquartered in Franklin, Tennessee.
95 Employees
Last Reported Date: 03/10/11
Founded in 1999
LAST $2.17 USD
CHANGE TODAY +0.03 1.40%
As of 8:09 PM 02/17/12 All times are local (Market data is delayed by at least 15 minutes).


04/8/11 - $14.49
01/9/12 - $1.87
BMTI Does Not Pay Dividends
K = Thousands  M = Millions  B = Billions

related news

No related news articles were found.


BioMimetic Therapeutics Inc. to Introduce Augmatrix(TM) Biocomposite Bone Graft Product Line at AAOS

BioMimetic Therapeutics Inc. announced that it will introduce Augmatrix(TM) Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distributors at its exhibit booth during the American Academy of Orthopedic Surgeons (AAOS) meeting this week in San Francisco. This Augmatrix product line is comprised of carbonate-apatite (calcium phosphate) and Type I collagen and is designed to be combined with bone marrow aspirate (BMA). The products are available in multiple forms to suit an array of bone grafting challenges, including fracture repair and general bone void filling procedures. The product line has been FDA cleared for use in orthopedic indications and is ready for sale in the United States. The addition of the Augmatrix product line will provide surgeons with a range of bone grafting solutions to procedures for which rhPDGF-BB based offerings will not initially be indicated. The Augmatrix bone graft substitute platform presents a perfect complement to existing orthobiologic portfolio and will allow to penetrate the large bone graft substitutes market earlier than anticipated. Adding offerings to the Augmatrix program with the goal of expanding the sales of these products through current distribution network, while establishing a commercial presence with surgeons and hospitals.

BioMimetic Therapeutics Inc. to Highlight Product Development Activities at ORS and AAOS Meetings

BioMimetic Therapeutics Inc. announced results of its 30 patient Canadian Augment(R) Rotator Cuff Graft clinical trial. The goal of the randomized (2:1), controlled study was to assess the safety and performance of Augment Rotator Cuff for primary surgical treatment of full thickness rotator cuff tears as compared to standard surgical repair (suture alone). The product achieved its primary safety endpoint, which was evaluated by a comparison of adverse events between the two treatment groups, and no device-related serious adverse events (SAEs) were reported. The results also indicated improvement in the clinical outcome assessments on DASH (Disabilities of Arm, Shoulder and Hand) and WORC (Western Ontario Rotator Cuff) index scores. Additionally, Augment Rotator Cuff was found to be user-friendly for the surgeons and required no additional operating room or anesthesia time over the current standard of care. BioMimetic also announced its schedule of events at the Orthopedic Research Society (ORS) and the American Academy of Orthopedic Surgeons (AAOS) meetings. These meetings are being held consecutively in San Francisco, CA beginning February 4, 2012. Additionally, the company will present preclinical studies featuring the use of rhPDGF-BB during the ORS and AAOS meetings. Paper #2198 entitled Augment(R) Bone Graft Products Compare Favorably to Autologous Bone Graft in an Ovine Model of Lumbar Interbody Spine Fusion will be presented by BioMimetic scientist, Dr. Luis Solchaga. The study, which demonstrated that BioMimetic's Augment products and the current standard of care, iliac crest autograft, are equivalent in this model of interbody spine fusion, will be presented by poster during the ORS Meeting from February 6 -- February 7 at the Moscone West Convention Center Level 3.

BioMimetic Therapeutics Inc. Presents at Canaccord Genuity Musculoskeletal Conference, Feb-07-2012 11:20 AM

BioMimetic Therapeutics Inc. Presents at Canaccord Genuity Musculoskeletal Conference, Feb-07-2012 11:20 AM. Venue: Parc 55 Wyndham Hotel, 55 Cyril Mangin Street, San Francisco, California, United States. Speakers: Samuel E. Lynch, Founder, Chief Executive Officer, President and Director.

BMTI Competitors

Company Last Change
CryoLife Inc $5.67 USD -0.31
Kensey Nash Corp $24.34 USD +0.43
RTI Biologics Inc $4.06 USD +0.01
Wright Medical Group Inc $16.75 USD +0.07
Zimmer Holdings Inc $61.53 USD -0.01
Market data is delayed at least 15 minutes.

Industry Analysis

Valuation BMTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.6x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful



BMTI transactions

No transactions in the last 6 months.
No related news found for this Biomimetic Therapeutics Inc.

Write Comment Create Account

Quotes are delayed for NASDAQ, NYSE, OTC, OTCBB (Penny Stocks) and NYSE Amex when available. Quotes and other information supplied by independent providers and feeds. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Localnewsnor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing Localnews, you agree not to redistribute the information found therein.

Privacy Policy - WE KEEP YOUR PERSONAL DATA PRIVATE AND CONFIDENTIAL - Localnews is committed to protecting the privacy of all our visitors and subscribers. Your right to privacy is very important to us. When you choose to provide us with information about yourself, we recognize that you trust us to act in a responsible manner. SHARING OF INFORMATION - Localnews does not sell, rent, lease or share any user information that it has collected over this website.

@2012 - Contact Us / Privacy Policy